Frontiers in Oncology, 2021 BackgroundChordoma, an extremely rare malignant tumor, remains difficult to be cured because of its strong local invasiveness and high recurrence rate. Long non-coding RNAs (lncRNAs) have been demonstrated to play multiple roles in various cancers.
Kai Zhang +10 more
doaj +1 more source
Cell Reports Medicine, 2021 Summary Chordomas are rare spinal tumors addicted to expression of the developmental transcription factor brachyury. In chordomas, brachyury is super-enhancer associated and preferentially downregulated by pharmacologic transcriptional CDK inhibition ...
Hadley E. Sheppard +18 more
semanticscholar +1 more source
Expression of
Journal of Experimental & Clinical Cancer Research, 2010 Background Chordoma was a typically slow-growing tumor. The therapeutic approach to chordoma had traditionally relied mainly on surgical therapy. And the main reason for therapeutic failure was resistance to chemotherapy and radiotherapy.
Ma Baoan +8 more
doaj +1 more source
A novel chordoma xenograft allows in vivo drug testing and reveals the importance of NF-κB signaling in chordoma biology. [PDF]
PLoS ONE, 2013 Chordoma is a rare primary bone malignancy that arises in the skull base, spine and sacrum and originates from remnants of the notochord. These tumors are typically resistant to conventional chemotherapy, and to date there are no FDA-approved agents to ...
Matteo M Trucco +15 more
doaj +1 more source
Targeted therapy for chordoma: key molecular signaling pathways and the role of multimodal therapy
Targeted oncology, 2021 Chordoma is a rare but devastating tumor that arises in the cranial skull base or spine. There are currently no US Food and Drug Administration-approved targeted therapies for chordoma, and little understanding of whether using more than one therapy has ...
O. Akinduro +7 more
semanticscholar +1 more source
The comparative integrated multi-omics analysis identifies CA2 as a novel target for chordoma.
Neuro-Oncology, 2021 BACKGROUND Chordoma is a rare mesenchymal malignancy, with a high recurrence rate and unclear tumorigenic mechanism. Genetic alterations, epigenetic regulators, and chromatin spatial organization play crucial roles in the initiation and progression of ...
T. Meng +13 more
semanticscholar +1 more source
CMTM3 suppresses chordoma progress through EGFR/STAT3 regulated EMT and TP53 signaling pathway
Cancer Cell International, 2021 Chordomas are rare, slow-growing and locally aggressive bone sarcomas. At present, chordomas are difficult to manage due to their high recurrence rate, metastasis tendency and poor prognosis.
W. Yuan +6 more
semanticscholar +1 more source
MicroRNA-608 and microRNA-34a regulate chordoma malignancy by targeting EGFR, Bcl-xL and MET. [PDF]
PLoS ONE, 2014 Chordomas are rare malignant tumors that originate from the notochord remnants and occur in the skull base, spine and sacrum. Due to a very limited understanding of the molecular pathogenesis of chordoma, there are no adjuvant and molecular therapies ...
Ying Zhang +3 more
doaj +1 more source
Recurrent Metastatic Chordoma to the Liver: A Case Report and Review of the Literature
Current Oncology, 2022 Chordoma is a rare malignant neoplasm derived from notochordal tissue that primarily affects the axial skeleton. Almost 40% of patients have non-cranial chordoma metastases.
Thomas E. Dickerson +8 more
doaj +1 more source
Carbon ion radiotherapy for sacral chordoma: a retrospective nationwide multicentre study in japan.
Radiotherapy and Oncology, 2020 BACKGROUND AND PURPOSE Usefulness of carbon ion radiotherapy (CIRT) for sacral chordoma has been reported from single institutions. We conducted a retrospective nationwide multicentre study to evaluate the clinical outcomes of CIRT for sacral chordoma in
Y. Demizu +11 more
semanticscholar +1 more source